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Indolent, primary cutaneous T-cell lymphomas 
(CTCL) are characterized by hyper-proliferation of 
malignant T -helper cells in the skin with a favorable 
prognosis in the early stages. Cytotoxic T cells (CTLs) 
are believed to be of major importance for tumor 
surveillance, but there is not yet sufficient evidence 
for a systemic anti-tulnor response in Inycosis fun-
goides (MF). On the contrary, there are hints of 
systemic immunodepression. We wondered whether 
signs of a systemic anti-tumor response were demon-
strable in peripheral blood of patients with MF and 
CD3 0+ ple omorphic T cell lymphoma. Using mul-
tiparameter flow cytometry, we investigated blood 
samples from 39 CTCL patients at different stages 
and compared them with those from patients with 
psoriasis, atopic dermatitis, and healthy volunteers. 
In CTCL patients, an elevated number of lympho-
cytes expressing natural killer cell markers were 
found, as well as considerable T-cell activation, indi-
cated by increased percentages of T cells expressing 
M ycosis fungoides (MF) and CD30+ pleomorphic T -cell lymp homa (TCL) are characterized by a autonomous proliferation of malignant CD4 + T -helper cells with a filVo rable long- term sur-vival , currently regarded as indolent , primary 
cutane ous T cell lymphomas (CTCL) by the European Organiza-
cion for Research and Treatment of Cancer. Cutaneous Lymphoma 
Project Group. T he freque nt multifoca l or diftllse cutaneous distri-
bution suggests t11at neoplastic T cells in CTCL selectively recir-
culate to skin (Ede lson, 1980). Recent results , however, indicate an 
early sys temi c spread of these neoplasti c cells long before clinical 
appeara nce of extracutaneous manifestations (Bunn et nl, 1980; 
Dommann ct nl, 1996; Muche ct nl, unpublished observations). 
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Abbreviations: CTLs. cytotoxi c T lymphocytes; IL-2R. interleukin 2 
receptor a - chain ; LFA-l. leukocyte fu nction-associated antige n 1; MF. 
mycos is fungoides; TCL. T cell IYl'lphol11a. 
HLA-DR, IL-2 receptor a - chain, and transferrin re-
ceptor. The CD8+ T cells, which were the most 
strongly activated T-cell subset, were of polyclonal 
origin, as shown by their usage of different T-cell 
receptor families. The enhanced expression of acti-
vation antigens was associated with an increased 
proportion of CD8+ T cells with high expression of 
the adhesion molecule LFA-l, demonstrating the 
capacity for migration of these cells. These CD8+ 
effector cells are suspected to be CTLs and may be 
responsible for the favorable prognosis of indolent, 
primary CTCL. Interestingly, a stage-dependent de-
crease in T-cell activation antigen expression was 
observed, suggesting the development of a lack in 
tumor surveillance in advanced MF stages. Further 
investigations are necessary to verify whether any of 
the paralneters determined are of predictive value for 
prognosis and response to therapy in CTCL. Key 
lVords: CTCLI"'J,cosis .filllgoldesIT-cell activatiolllCTLINK 
cells. ] [livest De,.lIIato[ 108:743-747, 1997 
Moreover, eosin ophilia, e lc vated IgE and IgA levels, and several 
other phenomcna give evidence for general immun e dysregulation 
in CTCL patients (reviewed .in Edclson. 1980). The data suggest 
that indolent, pl;mary CTCL is likely to be a systemic disease even 
if a progressive extracutaneous spread is no t yet clini cally apparent. 
It has been shown that ac tivated tumor-infiltrating CDS + T cell s 
are present in .MF Ski)l les ions. In terestingly, lower numbcrs of 
t11cse cytotoxic T cells (CTLs) correlate with Icss f.worable prog-
nosis (Hoppe ct nl, 1995) . Moreover. immunoprotection against a 
murinc CD4+ T cell lymphoma is mediated by ClImor-specific 
CTLs. I These findings underline the clini cal importance of acti-
vated T cells against lymphoma. Although an anti- tumor T-cell 
response was suggested by findin gs in skin lesions. there is not yet 
sufl-lcient written evidence for a systemic anti-tumor response in 
ME A recent examination demonstrates a relative decrease of T 
cells with a naive phenotypc ill M F patients but gives no direc t 
evidence for enhanced expression of T -cell activation or ll1Cl110ry 
antigens as signs for active immune processes (G ilmore et nl, 199 1) . 
I Berger C. Yang S. Felli A, Perez M. Edelson R: 1111111unoprotcction 
aga illSt " l11urine CD'I + T ce ll lymphoma is m ed ia ted by tumor-specifi c 
cytotoxic T cells. J 1"I'l'sr Dcn"nro!1 06:92 1. 1996 (a bstr). 
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Table I. Enhanced Expression of Natural Killer Cell Antigens in Primary Cutaneous T Cell Lymphoma a 
"' MF CD30+ TCL Pso riasis AD Contro ls 
(n = 31) (n = 8) (n = 26) (n = 19) (n = 21) 
"\ 
C D1(, + NK ce ll s ('X,) '18.03 :!: 1.87" '18.25 :!: 3 .34 14.88 :!: 2.22 12.05 :!: 1.% 13 .71 ± 1.31 
(Cpt/liter) 0 .36 ± 0.05 0.21 ± 0.03 0.24 :!:: 0.34 0.27 :!:: 0.04 0.23 :!:: O. O~ 
CD57 + lymphocytes (' :;,.) 21.93 ± 2.22" 18.25 :!:: 3.49" 13.92 :!:: 1.79 11.47 :!: 1.58 12.95:!::1. 21 
(Cpt/ li rer) 0.46 ± f).Duc 0.26 ± 0.07 0.24 :!:: 0.03 0.23 :!:: 0.03 0.21 :!:: 0. 0, 
C D 19+ 8 ce ll s ('Yo) 9.90 :!:: 1. 42 7.62 ± 1.82'/' 10.12 :!:: 0.97 J 1.36 :': 1.71 8.71 ± 0.53 
(Gpt/liter) 0.25 :!:: 0.07 0.11 ± 0.03" 0. 18 :!:: 0.02 0.31 :!:: 0.05 0.17 ± 0.01 
C D3 + T cells (%) 72.32 ± 2.23' 72 .63 :!:: 4.79 73.81 :!:: 2.17 75.79 ± 2.15 77.57 ± 0.89 
(Cpt/ lireI') 1. 49 ± 0.13 0.99 ± 0.16" 1.32 ± 0.12 1.61 :!:: 0.20 1.46 :!:: 0.10 
CD4 + T cells ('X.) 45.35 :!:: 2.27" 43 .25 :!:: 4.93/' 45.04 ± 1.96/' 52.68 ± 2.66 49.23 :!:: 1.96 
(Gpt/ liter) 0.93 ± 0.09 0.59 :!:: f) .li'" 0.82 :!:: O.OS" 1.19 :!:: 0.15 0.95 ± 0.07 
CDS + T ceUs ('Yo ) 25 .22 :!:: 1.49 26.87 :!:: 5.58 26.92 :!:: 1.78 25.42 :!:: 2 .83 25.52 :!:: 1. 2~ 
(Cpt/ li te r) 0.53 ± 0.06 0.42 ± 0.09 0.58 :!:: 0.05 0.68 ± 0. 12 0.55 :': 0.0' 
CD4/CD8 ratio 1.8() :!:: O.19" 1.76 :': 0.38 1 .50 ± 0.11" 1.96 :!:: 0 .19 1.77 ± 0 .1? 
"\ 
" LYll1phoc)'£c subpopuiatiOllS were dCI"I.! nnincd using flo w C)'to lllctriC analys is as described in Mrltcritlls IJl/tI IVlct}/(lds. AhsoluU! numhers werc ca\cu\:ncd by nH~an s of white blQ~ 
ce ll COUl1 ts and diffcl'clltinl bl ood smear. Va lues nrc mean ::t SElv1. Mr:, mycosis fungoidc s; Tel, T ce ll lymphoma: AD, atopic dermatitis. 
" p <: 0.U5 jltTS/IJ AD: Mann-Whitney U-Tcsr . 
. p < (I.llS V(' l'sn s psoriasis. AD, "Ilel CO il tro is. 
II p < lUIS lIi'l'SlI,I' psoriasis . 
.. p < n.05 1'l" 'S IIS conrrols. 
Moreover , nmnerous investigations indicate an immullocomprised 
state in CTCL (Edeisoll, 1980). 
We h ypoth esized that a strong systemic anti-tumor immun e 
resp onse may contribute to the favorable prognosis of earl y stage 
M F and CD30 + TCL. T h erefore, we investigated lymp hocyte 
subpopulations and express ion of T-ce ll activation markers in 
CTCL. Us ing rJ'iple-color Aow cytometry, we d e m onstrated maJ'k-
edly e le vated numbe rs of peripheral bl ood lymphocytes expressin g 
natural killer ce ll (NK) alld T-cel l ac tivation antigens in early but 
ll Ot in la te CTCL, su ggesting a stage-depende n t systemic anti-
tulllor response. 
MATERIALS AND METHODS 
Patients Blood samples were obtai ned from adul t patients with c urrently 
un treated CTCL (ll = 39) , chron ic plague psoriasis (I') = 26) , atopic 
d"nn~titis (n = [ '), and he~ l th )' vo luntee rs (n = 2'1) . As determined by 
clinica l and histo logic/ immunohistologic criteria (Ked and Sterry, 1987) , 
samples from patients with stage 1 (n = 2 \ ), stage 1.1 (n = 8), and stage 
Ill- IV (n = 2) MF, and CD30 + pleomorphic T C L (n = 8) were coll ected . 
In nine of 25 CTCL patient~ investigated. the diagnosis was further 
co nfinllcd by che detecti o n of Jll O nOd0J1;11 T - ccJJ expan sion in .skin biopsies 
using a polymerase chain reacti on technique (Mu cho ci 01. unpublished 
observations). Moreover , in 11 of 27 CTCL p"tiems, monoclonal T-cell 
expansion was decected ill the peripheral blood. Patients with clinical 
ev idence for in fectio n 3 wk prior to admission were excluded. T h e stud y 
w"s appro ved by our Jns titutio nal I~cv i ew Board. Info l'lll ed consent was 
obtained f!'Om th" pati" nts. 
F low Cytolnetric Analyses of Lymphocyte Antigen Expression 
W hi te blood c,,11 COUll t w;\s expressed ill gigap<lrticlcs (Gpt)/ Iitcr (1 
Gpt/ litcr = 1000 cells/ r,d) , ilnd leukocyte popubtions were dcrermined 
using Neubauer 's chamber (Neubauer, Maricnfeld , German y) and differen-
tia l blood "meal', respectively. For rh e dete rmination of leukocyte antigen 
ex pression, peripheral blood mononuclear cell s were iso lated by Ficoll-
Hypaquc (Pharm"cia, Upps" la, Sweden) density grad ient centrifugation and 
speciti call y swined by phycocrythrin-. lluorescein isothiocya nate-, peJ'i-
din inc chloroph yll protcin- , alld R-ph ycocr),thrin cyanine 5-conjugated 
111 0 l1 oclonai anti b odies. Ce ll sta inin g waS pc rfo nne d acco rdin g to standard 
procedures described elsewhere (Picker cf ai , 1993: Kem et nl , 1996). Flow 
cytoll1ctri c ana\ ysis Wt\S pe rfo nnc d using FACScan equ ipmell t and Lysys II 
software (both Becton Dickinson, San Jose, CAl. Isotype controls (lgGl. 
IgG2a) were used for delineating 'pos iti ve' and ' negative' populations. 
rlcsuits arc exp ressed as the p erce nta ge of posit ive ce lls \-\'il:hil1 the 
populatio ns of interest and abso lute number of positive ce ll s. For the 
discrimination of CD 1'1 a-high and -low expressing T cc ll ~ , the cursor was 
set acco rding to the d ichoro llli c C D II a dist"ibution in the CD8 + T - cell 
population (Kern cl 01, 1996 ; see also Fig J). 
M o noclonal antibo di es 'w e re lI sed against the fo llowing a_llrige ns (clo ll es 
in parentheses): human leukocyte antigen (I-lLA-DR) (L243), CDI{ 
(M0P9) , Becton D ick inson, Heidelberg, German y; interl eukin 2 recep[o~ 
a -chain (IL-2R.)- C D25 (B'l.49.9), transferrin receptor-C D71 (YDJ 1.2.2), 
LFA-l a - chain-CDU .. (25.3.1), CD3 (UCHTt), CD4 (1368.2), CD 
(D9.JJ), CDl6 (3GB), CD19 04 .119) , CD57 (NC1), TCIU3V2S1 
(E22E7 .2), TCIU3V3SI (LE-89), TC1U3V6S1 (CR.T304.3) , TCIU3VSSl 
(56C5.2). T C IU3Vl1S1 (C21) , TCIU3V12S2 (VER2 .3 2.1), TCRBV1 3S1 
(lMMU222), TCRBV13S6 QU74.3) , TCR1W14S1 (CAS1.1.3). TCRVBI 6S1 
(TAMAYA1.2), TCRBV17S1 (E17.SF3.15. 13), T C lU3V20S 1 (ELLl.4), 
TCIlVIl21S3 (JG.12S), TCRVB22S1 (IMMU546) , Conlter-Immunorech, 
Hamburg, Gerll1an y: TCIU3V5S1 (LC4), TCR13VSS2,S3 (ICI). T CIU3VSS3 
(W112), TCRBV6S7 (OTI45), TCRBV8 (MX-6) , TCRB V1 2 (S511), T CeU 
Diagnostics , DPC Biemlann, Bad Nauhcim, Germany. 
Statistical Analysis Data are expressed as mean ± SEM. M,\t\n-Whir:ne~, 
U-Test (SPSS software) was used for the comparison of gro ups. Wilcoxo~ 
Test was used lu I' comparison of T -cell slIbsets in paired samples. Differ, 
ences were considered signifi cant at p < 0.05. 
R.ESULTS 
Leukocyte and Lymphocyte PopUlations Whereas leukocYt~ 
(7.34 :!:: 0.36 Gpt/liter), neutrophil (4.37 :!:: 0.23 G pt/ lite r), all~ 
monocyte (0. 55 :!:: 0.05 Gpt/liter) cOllnts in patients with MF wer~ 
sig njficantly hig he r than in healthy controls (5.72 :!:: 0.35,3.30 :! 
0.26 , and 0.36 :!:: 0.06 Gpt/liter, respectively), patients witl) 
CD30+ TCL sh owed a signifIcant decrease in le ukocyte (4.58 :! 
0.28 G pt/L) and lymphocyte numbers (1.33 :!:: O. '17 verSlls 1.89 :!: 
0.12 Gpt/ lite r in controls). No significant changes ill le u koc)'~ 
po pulatiolls were d emonstrated between patients with differellt 
stages of MF (data not sh own). 
T he relative and absolute numbers of lymph ocyte su bpopula, 
tions, as revealed by Aow cytometric analyses , are shown in Tabl~ 
I. No significant changes in Mf patients were fo ulld whe n anal ),z, 
ing the absolute T - and B - ceU numbers . III p ati e nts with CD3 0 
TCL, h owever, the T - ce ll populatio n was sign ifIcantly dlminished 
in comparison to the control g roup due to a significantl y decreased 
number of CD4+ cells . [n both CTCL patient groups, CD30 J. 
TCL and MF, the proportion of CD16+ NK cell s and CDS7 .!. 
lymphocytes was higher than ill healthy contro ls and in patieuu 
w ith n o nm'llignant dermatologic diseases (p < 0.05). When COlll-
paring the proportion ofCD16+ and CD57+ lymphocytes in earl) 
(stage I) with more advanced MF stages (> stage I) , we found I 
tenden cy for stage dependency. In stage I MF the proportion of 
CD16+ (18.57 :!:: 2 .0'X,) and CD57 + lymphocytes (23.86 :!:: 2.45%) 
was higher than in the m ore advanced stages (16 .9 :!:: 3.5 ;Uld 
1.7. 9 :!:: 3 .2% , respectively) . Although this difference was not 
VOL. 108. NO. MAY 1997 
25
1 
: 
20 
+ 
J!l I ~ 15 
"' ~ + ;-
8. 10 1 + 
* 
I T 
I 
MF 't~pe I M~ ' L'~ II MF stage III 'IV C03Q ' Tel Pt.Orl .... , I,eallny ConIrOiI 
!n~2q r,, ' " !n-21 1" &') 1""'61 ("Hi) i"-:I ) 
Figure 1. Proportions of T cells expressing activation markers are 
increased in stage I MF but decrease with MF progression. Percent-
ages ofHlA-OR.., Il-2R (a chain-CD2S) . and TfR. (CD71)-positive T cell s 
were determined by double-color flow cytomctry as desclibed in Materials 
a/ld Methods. Values arC shown as m ean ::':: SEM. MF, Mycos is fungoides; 
TCL, T cell lymp homa; AD, atopic dermatitis; ' . p < 0.05 v"rslls psoriasis. 
atopic dermatitis. and healthy control s; +, p < 0.05 IIerSIl S healthy controls; 
Mann-Whitney U-test 
statis tically significant, the values in MF stage I, but not in the more 
advanced stages, were significantly higher than in healthy volun-
teers (p < 0.001 for CD57) or just failed to be significant (p = 0.07 
fo r CD16) . 
Enhanced T-Cell Activation Marker Expression Restricted 
to Early MF Frequencies ofT cells expressing HLA-DR, IL-2R 
(CD2S), and transferrin receptor (CD71) , considered to be acti-
vated T cells , were determined flow cytometricaUy. The percentage 
of T cells expressing HLA-DR in stage I, but not in the more 
advanced stages of MF, was significantly higher tllan in patients 
with atopic derma titis or psoriasis or in healthy controls (Fig 1). 
Enhanced proportions of HLA-DR + T cells compared to healthy 
controls were also demonstrated in patients with CD30+ TCL, 
psoriasis, and atopic dermatitis but were significantly lower than in 
MF stage I. Similar results were observed for CD71 positive T cells. 
Again, MF stage I showed the highest level. Additionally, the 
frequency of IL-2R expressing T cells was elevated in stage I MF, 
but not in the more advanced stages. Taken together, the data 
indicate that the proportion of activation antigen-expressing T cells 
decreased in a stage-dependent f.1shion £i'om enhanced values in 
MF stage I to proportions not distinguishable from tllOse in healtllY 
controls in stage III + IV of MF. A markedly enhanced expression of 
T cell activation antigens was also observed in patients with 
CD30+ TCL (Fig 1). 
HLA-DR Antigen Expression Is Predominantly Increased 
OD CD8+ T Cells in CTCL Next we tried to determine the 
T-cell subset(s) eJ.:p ressing activation antigens in increased fre-
quency. Therefore, in a subpopula tion of patients, we investigated 
the HLA-DR antigen expression separately on CD4+ and CD8+ T 
cells (Table II). In CTCL patients (3 X MF stage I, 2 X MF stage 
U, 4 X CD30+ TCL) the percentage of HLA-DR-expressing 
CD8 + T cells was signifi cantly higher than in patients with 
psoriasis or atopic dermatitis, or in healthy controls. Moreover, the 
frequency of HLA-DR + CD4 + T cells in CTCL patients was also 
significantly higher than in controls. The proportion ofHLA-DR + 
r cells was m arkedly higher in the CD8 + than in the CD4+ subset; 
however, the difference was not statistically significant (p = 0.08; 
Wilcoxon Test). 
Polyclonal TCR V{3 Usage of HLA-DR+ CD8+ T Cells in 
CTCL To further charactel; ze the activated cells, we investigated 
the T-cell receptor (TCR) {3-chain usage of HLA-DR + T cells in 
three patients with MF and one patient with CD30+ TCL (data not 
shown) . The monoclonal antibody panel for TCR V {3-families 
covered about 60-70% of all TCR a{3-positive T cells in our 
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Table II. Enhanced HLA-DR Antigen Expression on 
Circulating CD4+ and CD8+ T Cells in Cutaneous T Cell 
Lympholua in Corn.parison to Psoriasis, Atopic 
Dermatitis, and Controls" 
CTC l 
Psoriasis 
AD 
Controls 
(n = 9) 
(n = 5) 
(n = 5) 
(n = 6) 
HLA-OR 0 11 I-ILA-DR 0 11 
C08 + lymphocytes (,X») CD4 + lymphocytes (%) 
2 1.01 ::':: 4.63
'
< 
7.42 ::!: 0.85 
7.49 ::':: 1.78 
4.94 ::!: 0.81 
13.48::':: 2.1 1" 
5.20 ::!: 0. 82 
4.80 ::':: 1.28 
5.05 ::!: 0.42 
" HLA-OR antigen expression o n C D-I + and C DR + T cells was dcccrminco using 
trip le-color flow cytom crry ilS described ill NI(Jf{.'rja/s " li d ill/Clilods. PCl'c c lltagc of pns iriv~ 
cells is m c:t ll ::!: SEM. CT C L, cutaneous T cell lympho l11:l; AD. ntopic dermatitis. 
/. p < 0.05 ,nnw. psori:lsis. AD. and co ntrols. M:mn-Whitllcy U-TCSL 
,- HLA-OR expression 011 C 0 8+ /'1' I'5 I/S CD..J + T cells was n OI sratiHicnll v ditferellt 
(p = 0.08: Wilcoxon-Test). ' 
,f P < 0.05 " Cr.'i Il S AD. and cOlltrols; Mal1.1l-\Vhirncy U-Test. 
patients. In all four patients, no T-cell subpopulation defin ed by its 
TCR V{3-family represented m ore than 10':10 of the total number of 
all activated T cells. Although the distribution of HLA-DR + T 
cells, considered to be activated , was not randomly di stributed 
among the distinct TCR V{3-families, suggesting a bias in the TCR 
usage of activated T cell s, there were no signs of clonal expansion. 
CD8+ T cells particularly showed cnhanced HLA-DR cxpression 
in at least hal f of the V{3-families studied. 
CD8+ T-Cell Activation in Early MF Is Associated with 
Enhanced Leukocyte Function-Associated Antigen 1 
(LFA-1) Expression N ext we studied the expression ofLFA-1 on 
peripheral blood T cells in CTCL, inasmuch as this adhesion molecule 
is involved in targeting memory-type T cells to sites of chronic 
inflammation (Santamaria Babi et ai, 1995). T he frequency oftlle high 
LFA-l a-chain (CD11a)-expressing cells was determined flow cyto-
metrically witlun the different T-cell subsets. As shown in Fig 2. the 
percentage of high CDlla expression paralleled the T-cell activation 
an tigen expression in CTCL patients; i.e ., it was significantly increased 
in stage I and declined in more advanced stages. Interestingly, in st~l ge 
III + IV MF the levels seem to be even lower than in the cono'ol 
population (n = 2, not significant) . In particular. as for the oche,' 
activation markers, the CD8 + T cell subset conu;bmed mainly to tlle 
enhancement in early stage MF. 
To further assess tlle relation between T-cell activation (HLA-
DR antigen expression) and high expression of the adh esio'n 
I~ cos. T-cells I T all T-cells CO-1+ T-cells 
i-L U
1 ~ ~ fL"" f-t-
~ l.:r.. "'1 
rh ~ I I 
MF s!agt! MF lllga n MF,tag.m.lV COlO' TCl P,Ma", AO HuU"r~' 
1.,..21) 1",,8) 1 .... 2) In-81 ( .... 26) (n~191 ("':21) 
Figure 2. Enhanced proportion of circulating CD8+ T cells ex-
pressing high level ofLFA- l in MF stage J. Percentages ofCD4 + and 
CDS + T cell s with high-l evel expression of lFA-l were determined using 
a monoclonal antibody against lFA-1 a -chain (C D 11 a) in trip le-color Aow 
cytometry as described in N/arl'linls alld Methods. Values arc m ean ::!: SEM. 
MF. Mycosis fungo ides; TCl, T cell lYlllphoma; AD. atopic dermatiti s; ' . 
p < 0.001 lIers lls CD30+ TCl. psoriasis. aropic dennatiris. alld control s: +. 
P < 0.05 IIt' /'SIIS psoriasis. atop ic dennatitis. and controls: Mann-Whitney 
U-test 
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Figure 3. Typical expression pattern ofLFA-1 and HLA-DR anti-
gen on circulating T cells in a p"tient with MF stage I (B) in 
comparison to control (A). Expression of LFA-l a-chain (CDll a) and 
j-ILA-DR on circulating CD4+, CD8 + , and CD3 + (all) T ce lls was 
investigated by trip le-colat flow cytometry as described in Mater;als ""d 
Methods. Typical examples for peripheral blood T ce lls from a patient with 
MF stage I (B) and a control proband (A). respectively, arc shown. The 
one-para meter histograms give the COlI a expression pattern and the 
percentages of high-CDlla-expressing cells for each T-ce ll population 
(CD4 + , CDS +, and CD3 + (all) T cells). The cu rsor was set according to 
the dual d istribution of CDI j a expres.,ion on CD8+ T cells. The two-
pa .. ;) meter histograms show the pattern of HLA-DR antigen expression 
dependent from CDl. ·\ a expression within tl,e different T-cell populations. 
molecule CD11 a, we inves tigated the direct relationship between 
the two markers in five patients with MF using t1'iple-color flow 
cytometcy. Figure 3 shows the staining pattern of peripheral blood 
T-cell subsets from a representative patient with MF stage J (Fig 
3B) in comparison with a control proband (Fig 3A). In this typical 
case, almost all HLA-DR-expressing T ceUs from the CTCL 
patient belonged to the CD11 a-high CDS + subset. 
I.n summary, these data indicate an association of stage-depen-
dent expression of adhesion molecules and T-cell activation anti-
gens on the CD8+ T ceUs 6'om CTCL patients. 
DISCUSSION 
The striking findings in our iJ11111Unop!lenotypic characterization of 
leukocytes in indol ent, primary CTCL were dle increased numbers 
of lymphocytes with NK cell markers and a marked enhan cement 
of polyclonal CD8 + T cells expressing activation antigens as well 
as high LFA-l. Interestingly, this was restricted to early-stage MF 
and declined in more advanced stages. Activated CD8+ T cells 
(MHC class I-restricted CTLs) and CD16+ NK cells (not MHC 
I-restricted) represent two major populations of cytotoxic lympho-
cytes and are beHeved to be of major importance for anti-tumor 
respome (Kos and Engleman, 1996). 
Although systemic T cell activation is desnibed in atopic derma-
titis and psoriasis (Sowden col ai, 1992),2 its exten ~ ~1 ou.1' study was 
2 Zhcng M, C hristophers E. Mrowictz U: Decreased chemotactic activity 
and increased activation ofT-lymphocytes in psoriasis and atopic derm!ltitis. 
J !lilIes! DCI'mn!o! J 06:924, 1996 (abstl'). 
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significantly lower chan in early stage MF. Moreover, Sowden el QI 
(1992) reported activation of circulating CD4 +, but not CDS +. 
lymphocytes in atopic dermatitis. The lymphocyte activation pat-
tern we found ill early-stage MF resembles, to a great extent, 
alterations very frequently observed iJl systemic vims infection 
(Docke e/ 111, 1994). As in tumor surveillance, the immune defense 
against viral infection depends largely Oll activated CTLs. NK cell s, 
and their m ediators. Recently, we demonstrated that an enhanced 
proportion of circulating CD57+ lymphocytes in cytom egaloVirus 
infection is associated Witll a profoundly increased expression of 
interferon-)! and tumor necrosis factor-a mRNA. This was 1' ..... 
stricted to the expanded, LFA- l high-expressing T-ceU popUlation, 
which also showed increased HLA-DR expression (Kern et ai, 
1996). The quite similar phenotypic alterations in early-stage MF 
suggest functional immunoactivation against cellular antigens. In-
terestingly, the lack of a typical lymphocytic activation pattern ill 
response to cytomegalovirus infection in immunosuppressed pa-
tients was associated Witll an unfavorable clinical course (Dacke er 
ai, 1994), as is also the case in advanced MF. 
It has been shown that LFA-l and the cutaneous lymphocyte-
associated antigen, which is predominantly expressed on activated 
T cells, are involved in the adhesion and migration of skin- homing 
T cells across cytokine-activated human endothelial cell layers 
(Picker el ai, 1993; Santamaria Babi el aI, 1994). Therefore, tile 
elevated proportion of circulating LFA-l high-expressing, HLA-
DR + T cells in early CTCL may have the potential for skin 
infiltration . Infiltration of HLA-DR + CDB + CTLs has beel] 
demonstrated in MF skin lesions and was found to be positively 
correlated with patients' long-term survival (Hoppe ct ai, 1995). 
Moreover, in melanoma, an iJ1CreaSe in HLA-DR + T cells after 
treatment with recombinant interferon-y and - a was associated 
with a longer survival (Osanto el nl, 1989) . Taken together, these 
data suggest that activated CD8+ T cells are of importance for 
immune ·surveiUance in malignant dermatoses such as CTCL. 
In more advanced stages of MF, we observed a declin e in the 
proportion of high LFA-l-expressing activated T cells . Accord-
ingly, to this, a stage-dependent decrease in local CD8+ T-cell 
infrltration" (Hoppe el aI, 1995) and the development of systemic 
immullodep(ession in advanced MF was described (Edelson, 1980; 
Dummer c/ ai, 1993). Our data, indicating a loss ofT-cell activation 
in adva!lced MF stages, further extend the knowledge of the 
development of immunodepression bel ieved to be responsible for 
further tumor progression and an enhanced risk for secondary 
malignancies in CTCL (Kantor et ai, 1989). 
Very recently we demonstrated increased iJlterleukin- l0 mRNA 
expression in skin lesions of advanced MP stages (AsaduUah cr. ai. 
1996). This cytokine downregulates antige n-presenting capacity of 
Inacrophages, as well as lymphocytic T -helper 1 and CTL ftmc-
tions, and prptects malignant cells from tumor- specific CTLs (De 
Waal Malefyt el ai, 1991; Matsuda et ai, 1994). In addition to 
immul1odysregulation by malignant cell-dedved immunosuppres-
sive factors, mechanisms of " immunologic escape" and clonal 
anergy or exhaustion may be respollSible for the loss of immuno-
activation in advanced MF (Rammensee e/ al 1989, Greenberg 
1994). 
We found a considerably elevated number oflymphocytes with 
NK cell and activation markers in CTCL restricted to entities with 
a favor<lble prognosis. Also, a recent outcome analysis of patients 
with stage IA MF demonstrated that their life expectancy was nor 
altered, and in less than 10% of these patients was progression of 
disease observed (J(j~ et ai, 1996). Additionally, a similarly favor-
able prognosis (5-y survival > 80%) was described for patients with 
CD30+ pleomorphic CTCL (Bcljaards el ai, 1993). In contrast, 
patients with advanced stages of MF, in whom we could not detect 
significandy elevated numbers of lymphocytes expressing activa-
tion markers, have a less favorable prognosis ~Lorincz, 1996). 
Interestingly, similar results as in advanced MF were demonstrable 
in two Sezary patients, supporting our conclusion that lack ofT-ceU 
activation may be of negative prognostic value. Remarkably, Prinz 
el al (1995) reported that in CTCL patients NK ce ll count 
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increased in responders afte r ex tracorporeal photopheresis. Further 
inv estigations are necessary, however, to evalu ate the prognostic 
value of T cell activation and NK cell number fo r lon g-ternl 
surveillance and response to therapy. 
T/Jis I/Iork lIIas slIpported II)' till' Dellts,"e Pvrsc:lllltlgsgellJeillscllnJr (Str 366 /7-1). 
We t"allk Pel "I' [lfl aldrll Ji' r cr;l;cal re//l arks. 
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